Skip to main
  1. Stocks
  2. Alto Neuroscience Inc
  3. Forecast
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is attractive fundamentally because its precision-psychiatry strategy uses EEG and other biomarkers to enrich for responders, which should improve trial signal quality and raise the odds of clinical success versus broad, noise-prone development. The lead programs look meaningfully de-risked: ALTO-300 builds on an EU-approved, generally safe agomelatine backbone with an expected 1H27 readout and roughly 50% biomarker enrichment, while ALTO-207 is supported by independent pramipexole data and a differentiated ondansetron-enabled titration strategy in a three-trial PACE program. Financially, about $338 million of pro forma cash is expected to fund operations through 2030, giving the company runway to reach multiple 2027 catalysts, including ALTO-300 in 1H27, ALTO-100 in mid-2027, and PACE-1 in 2H27.

Bears say

Alto Neuroscience is facing a weak fundamental setup because real-world pramipexole dosing is materially below the Phase 2 PAX-D trial, with an average maximum daily dose of 0.71 mg versus 2.3 mg and 78% titrating more slowly than labeled, raising doubt that ALTO-207 can translate clinical promise into commercial use. Its core monetization challenge is that pramipexole and ondansetron are both generic, so the asset must justify value as a combined product despite off-label substitution friction and payer barriers, while prior ALTO-100 execution also disappointed when the Phase 2b trial missed its primary endpoint. Financially, spending is already rising, with R&D at $22.1 million in 2Q26 versus $13.1 million in 2Q25 and net loss widening to $27.6 million, and the need for $150 million to $200 million of annual equity raises in 2027E–2029E points to significant future dilution.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

ANRO Analyst Forecast & Price Prediction

Get the latest ANRO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANRO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


ANRO Analyst Forecast & Price Prediction

Get the latest ANRO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANRO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANRO stock data and trends